OSE Immunotherapeutics SA announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment.
[OSE Immunotherapeutics]